IDH2 and acute myeloid leukemia: Enasidenib (IDH2 inhibitor) showed a significant increase in the survival rate in R/R AML IDH2 patients not eligible for HSCT [197], and, in a phase 3 trial, enasidenib displayed improved event-free survival compared to a conventional care regimen [198].